Background
==========

TLRs 2, 4 and 9 have been implicated in murine models and human patients of arthritis, but the other TLRs are not well-investigated. Thus, we studied TLR expression and signaling and effect of TLR ligand stimulation in peripheral blood (PB) and synovial fluid (SF) monocytes (MC) of ERA patients.

Methods
=======

Levels of TLR2, TLR4 and TLR9 were measured by flow cytometry in ERA PBMC (n = 26), paired SFMC (n = 13) and healthy PBMC (n = 19) Real time PCR was done for TLRs 1-9 and their adaptors IRAK1, IRAK4, TRIF, TRAF3, TRAF6. PBMC and SFMC were stimulated with ligands for TLR1 (pam3-cys), 2 (peptidoglycan), 3 (polyI:C), 4 (LPS), 5 (flagellin) and 6 (zymosan). Levels of IL-6, IL-8 and MMP3 (ng/ml) were measured in the culture supernatants.

Results
=======

ERA PBMC had higher MFI of TLR2 \[295.5(48.1-598) vs 179(68.7-442); p \< 0.05\] and TLR4 \[448(178-2581) vs 402(229-569); p \< 0.05\] compared to controls. Intracellular TLR9 expression showed no significant difference between both groups. In paired samples, SFMC had higher MFI of both TLR2 \[485(141-1683) vs 353(180-598); p \< 0.05\] and TLR4 \[1016(42.4-3159) vs 513(193-2581); p \< 0.05\] compared to PBMC. Difference in TLR9 expression was not significant \[[@B1]\]. Patient PBMC (compared to healthy control) and SFMC (compared to corresponding PBMC) had higher RNA expression of TLRs1, 2, 3, 4, 5 and 6 and downstream adaptors. Patients PBMC produced significantly higher IL-6 (13.51 vs 6.54) and MMP3 (61 vs 32.9) as compared to controls on stimulation by LPS. With peptidoglycan also IL-6 (30.58 vs 10.84) and MMP-3 (102.54 vs 49.45) was higher than controls. Patient PBMCs produced more IL-6 and IL-8 compared to healthy PBMCs on stimulation with Pam3-cys, poly I:C, flagellin and zymosan. In paired samples, SFMCs showed a trend towards higher IL-6 and IL-8 production compared to PBMCs (Table [1](#T1){ref-type="table"})

###### 

Production of IL-6 and IL-8 \[median (range) ng/ml\] by PBMCs and SFMCs upon TLR ligand stimulation.

  Cultured with   IL-6               IL-8                                                                                           
  --------------- ------------------ ----------------------- ------------------------ ------------------ -------------------------- ----------------
  Medium          4.4 (1.5-5.4)      7.6 (3-16.6) **\***     18 (9.3-24.2)            10 (4.3-12.6)      12.6 (8.1-35.7)            10 (4.3-12.6)
  TNF             13.6 (9.6-14.8)    16 (12-35)              21(18-30)                30.8 (15.8-36.3)   34.4 (30.8-46.1)           31 (15.8-36.3)
  Pam3cys         15.1 (13.3-19.6)   44 (26-62)**\*\***      53 (28-71)               37.1 (11.4-41.8)   106 (42.6-147.6)**\*\***   37.1 (11.4-42)
  PolyI:C         13.1 (1.3-25.8)    28 (24-4)**\***         46 (45-65)               33.6 (31.1-56.3)   126(78-167)**\***          34(31.1-56.3)
  Flagellin       14.1 (6.7-23.5)    34.9 (15-39.2) **\***   52.6 (40-53.8)**^\#^**   35.2 (16.1-84.2)   115 (73-162)**\*\***       35 (16.1-84.2)
  Zymosan         14.7 (8.8-36.3)    34 (28.4-39) **\***     48 (39.8-56.1)**^\#^**   56 (12.6-89.6)     106 (103-163)**\*\***      56 (12.6-90)

p \< 0.05\*\* 0.01 ERA PBMC versus control PBMC p \<^\#^0.05 ERA SFMC versus ERA PBMC.

Conclusion
==========

Increased TLR expression and signaling on PBMC and SFMC from JIA-ERA patients may exacerbate disease by upregulating IL-6, IL-8 and MMP-3 in response to microbial/ endogenous ligands. TLR pathway is a potential therapeutic target in these patients.
